{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:34:37Z","timestamp":1790321677642,"version":"4.1.0"},"reference-count":62,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,3]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>The HIF inhibitor ACF suppresses TKI-insensitive CML stem cells. The FDA-approved drug ACF may represent a novel treatment to prevent CML relapse and, in combination with TKIs, improve remission.<\/jats:p>","DOI":"10.1182\/blood-2016-10-745588","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T00:40:20Z","timestamp":1496450420000},"page":"655-665","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":81,"title":["Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine"],"prefix":"10.1182","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-3826","authenticated-orcid":false,"given":"Giulia","family":"Cheloni","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze Biomediche Sperimentali e Cliniche \u201cMario Serio\u201d, Universit\u00e0 degli Studi di Firenze, Florence, Italy;"},{"name":"Department of Medicine, University of Massachusetts Medical School, Worcester, MA;"},{"name":"Istituto Toscano Tumori, Tuscany, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2642-1706","authenticated-orcid":false,"given":"Michele","family":"Tanturli","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche Sperimentali e Cliniche \u201cMario Serio\u201d, Universit\u00e0 degli Studi di Firenze, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazia","family":"Tusa","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche Sperimentali e Cliniche \u201cMario Serio\u201d, Universit\u00e0 degli Studi di Firenze, Florence, Italy;"},{"name":"Istituto Toscano Tumori, Tuscany, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc","family":"Ho DeSouza","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Massachusetts Medical School, Worcester, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Massachusetts Medical School, Worcester, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Gozzini","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Funzionale di Ematologia, Azienda Ospedaliero-Universitaria Careggi (AOUC), Florence, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6984-7096","authenticated-orcid":false,"given":"Fr\u00e9deric","family":"Mazurier","sequence":"additional","affiliation":[{"name":"\u00c9quipe Niche Leuc\u00e9mique et M\u00e9tabolisme Oxydatif, G\u00e9n\u00e9tique, Immunoth\u00e9rapie, Chimie et Cancer, Unit\u00e9 Mixte de Recherche 7292, Centre National de la Recherche Scientifique, Universit\u00e9 Fran\u00e7ois-Rabelais de Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5949-3239","authenticated-orcid":false,"given":"Elisabetta","family":"Rovida","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche Sperimentali e Cliniche \u201cMario Serio\u201d, Universit\u00e0 degli Studi di Firenze, Florence, Italy;"},{"name":"Istituto Toscano Tumori, Tuscany, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoguang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Massachusetts Medical School, Worcester, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6411-569X","authenticated-orcid":false,"given":"Persio","family":"Dello Sbarba","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche Sperimentali e Cliniche \u201cMario Serio\u201d, Universit\u00e0 degli Studi di Firenze, Florence, Italy;"},{"name":"Istituto Toscano Tumori, Tuscany, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"14","key":"2019111904503105500_B1","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111904503105500_B2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"45","key":"2019111904503105500_B3","doi-asserted-by":"crossref","first-page":"16870","DOI":"10.1073\/pnas.0606509103","article-title":"Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice","volume":"103","author":"Hu","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019111904503105500_B4","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/sj.leu.2404224","article-title":"Hypoxia suppresses BCR\/Abl and selects imatinib-insensitive progenitors within clonal CML populations","volume":"20","author":"Giuntoli","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"2019111904503105500_B5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3324\/haematol.2010.029082","article-title":"Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate","volume":"96","author":"Giuntoli","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2019111904503105500_B6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"issue":"13","key":"2019111904503105500_B7","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1073\/pnas.0701152104","article-title":"Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia","volume":"104","author":"Parmar","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2019111904503105500_B8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jcp.21908","article-title":"The hematopoietic stem cell niche: low in oxygen but a nice place to be","volume":"222","author":"Eliasson","year":"2010","journal-title":"J Cell Physiol"},{"issue":"7","key":"2019111904503105500_B9","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V82.7.2031.2031","article-title":"The role of hypoxia in the maintenance of hematopoietic stem cells","volume":"82","author":"Cipolleschi","year":"1993","journal-title":"Blood"},{"issue":"1","key":"2019111904503105500_B10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0301-472X(01)00765-2","article-title":"Hypoxia maintains and interleukin-3 reduces the pre-colony-forming cell potential of dividing CD34(+) murine bone marrow cells","volume":"30","author":"Ivanovi\u0107","year":"2002","journal-title":"Exp Hematol"},{"issue":"1","key":"2019111904503105500_B11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1172\/JCI17669","article-title":"Expansion of human SCID-repopulating cells under hypoxic conditions","volume":"112","author":"Danet","year":"2003","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111904503105500_B12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.exphem.2010.01.005","article-title":"Hypoxia mediates low cell-cycle activity and increases the proportion of long-term-reconstituting hematopoietic stem cells during in vitro culture","volume":"38","author":"Eliasson","year":"2010","journal-title":"Exp Hematol"},{"issue":"5","key":"2019111904503105500_B13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1634\/stemcells.2006-0637","article-title":"Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells","volume":"25","author":"Giuntoli","year":"2007","journal-title":"Stem Cells"},{"issue":"2","key":"2019111904503105500_B14","doi-asserted-by":"crossref","first-page":"e17008","DOI":"10.1371\/journal.pone.0017008","article-title":"Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia","volume":"6","author":"Tanturli","year":"2011","journal-title":"PLoS One"},{"issue":"51","key":"2019111904503105500_B15","doi-asserted-by":"crossref","first-page":"84810","DOI":"10.18632\/oncotarget.13319","article-title":"Different BCR\/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction","volume":"7","author":"Bono","year":"2016","journal-title":"Oncotarget"},{"issue":"30","key":"2019111904503105500_B16","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.2174\/1381612811319300006","article-title":"The culture-repopulating ability assays and incubation in low oxygen: a simple way to test drugs on leukaemia stem or progenitor cells","volume":"19","author":"Cipolleschi","year":"2013","journal-title":"Curr Pharm Des"},{"issue":"3","key":"2019111904503105500_B17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s13238-013-2115-0","article-title":"Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells","volume":"4","author":"Zhang","year":"2013","journal-title":"Protein Cell"},{"issue":"2","key":"2019111904503105500_B18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-inducible factors and the response to hypoxic stress","volume":"40","author":"Majmundar","year":"2010","journal-title":"Mol Cell"},{"issue":"9","key":"2019111904503105500_B19","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111904503105500_B20","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2002-01-0109","article-title":"BCR\/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin","volume":"100","author":"Mayerhofer","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2019111904503105500_B21","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"42","key":"2019111904503105500_B22","doi-asserted-by":"crossref","first-page":"17910","DOI":"10.1073\/pnas.0909353106","article-title":"Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization","volume":"106","author":"Lee","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111904503105500_B23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.bloodjournal453321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"issue":"2","key":"2019111904503105500_B24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/stem.5530010205","article-title":"Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis","volume":"1","author":"Kubonishi","year":"1983","journal-title":"Int J Cell Cloning"},{"issue":"1","key":"2019111904503105500_B25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1365-3083.1996.d01-84.x","article-title":"Characterization of a human basophil-like cell line (LAMA-84)","volume":"44","author":"Blom","year":"1996","journal-title":"Scand J Immunol"},{"issue":"1","key":"2019111904503105500_B26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/MCB.7.1.379","article-title":"Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system","volume":"7","author":"DuBridge","year":"1987","journal-title":"Mol Cell Biol"},{"key":"2019111904503105500_B27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1083\/jcb.17.2.299","article-title":"Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines","volume":"17","author":"Todaro","year":"1963","journal-title":"J Cell Biol"},{"issue":"5","key":"2019111904503105500_B28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.stem.2013.08.011","article-title":"HIF-2\u03b1 protects human hematopoietic stem\/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress","volume":"13","author":"Rouault-Pierre","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"2","key":"2019111904503105500_B29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0006-3495(01)75733-5","article-title":"Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models","volume":"81","author":"Chow","year":"2001","journal-title":"Biophys J"},{"issue":"2","key":"2019111904503105500_B30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0006-3495(01)75732-3","article-title":"Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh\u2019s model","volume":"81","author":"Chow","year":"2001","journal-title":"Biophys J"},{"issue":"7","key":"2019111904503105500_B31","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/95.7.516","article-title":"YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1","volume":"95","author":"Yeo","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2019111904503105500_B32","first-page":"255","article-title":"A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent","volume":"29","author":"Kim","year":"2006","journal-title":"Int J Oncol"},{"issue":"4","key":"2019111904503105500_B33","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.bbrc.2006.08.015","article-title":"Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2)","volume":"348","author":"Lau","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"2019111904503105500_B34","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1158\/1535-7163.MCT-08-0074","article-title":"A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1alpha","volume":"7","author":"Li","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2019111904503105500_B35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4161\/epi.23538","article-title":"Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1\/ETO-positive leukemia cells","volume":"8","author":"Barbetti","year":"2013","journal-title":"Epigenetics"},{"issue":"4","key":"2019111904503105500_B36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.leu.2401744","article-title":"The expansion of murine bone marrow cells preincubated in hypoxia as an in vitro indicator of their marrow-repopulating ability","volume":"14","author":"Cipolleschi","year":"2000","journal-title":"Leukemia"},{"key":"2019111904503105500_B37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-4939-4011-0_7","article-title":"The culture repopulation ability (CRA) assay and incubation in low oxygen to test antileukemic drugs on imatinib-resistant CML stem-like cells","volume":"1465","author":"Cheloni","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"9","key":"2019111904503105500_B38","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity","volume":"189","author":"Li","year":"1999","journal-title":"J Exp Med"},{"key":"2019111904503105500_B39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-60761-058-8_15","article-title":"CML mouse model in translational research","volume":"602","author":"Peng","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"5","key":"2019111904503105500_B40","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2403332","article-title":"Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF [published correction appears in Leukemia. 2004;18(6):1164]","volume":"18","author":"Wellmann","year":"2004","journal-title":"Leukemia"},{"key":"2019111904503105500_B41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-015-0407-0","article-title":"BCR\/ABL1 and BCR are under the transcriptional control of the MYC oncogene","volume":"14","author":"Sharma","year":"2015","journal-title":"Mol Cancer"},{"issue":"7607","key":"2019111904503105500_B42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"issue":"1","key":"2019111904503105500_B43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/REP-09-0300","article-title":"Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions","volume":"139","author":"Forristal","year":"2010","journal-title":"Reproduction"},{"issue":"9","key":"2019111904503105500_B44","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1172\/JCI66129","article-title":"Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival","volume":"124","author":"Chen","year":"2014","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111904503105500_B45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2184.2000.00183.x","article-title":"Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats","volume":"33","author":"Jensen","year":"2000","journal-title":"Cell Prolif"},{"issue":"20","key":"2019111904503105500_B46","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.4161\/15384101.2014.964107","article-title":"The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy","volume":"13","author":"Rovida","year":"2014","journal-title":"Cell Cycle"},{"issue":"3","key":"2019111904503105500_B47","first-page":"235","article-title":"The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation","volume":"2","author":"Welsh","year":"2003","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2019111904503105500_B48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.605.65.2","article-title":"Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway","volume":"65","author":"Tan","year":"2005","journal-title":"Cancer Res"},{"issue":"20","key":"2019111904503105500_B49","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","article-title":"Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin","volume":"22","author":"Hudson","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2019111904503105500_B50","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-03-3139","article-title":"Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications","volume":"64","author":"Rapisarda","year":"2004","journal-title":"Cancer Res"},{"issue":"12","key":"2019111904503105500_B51","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/82146","article-title":"Suppression of tumor growth through disruption of hypoxia-inducible transcription","volume":"6","author":"Kung","year":"2000","journal-title":"Nat Med"},{"issue":"1","key":"2019111904503105500_B52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccr.2004.06.009","article-title":"Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway","volume":"6","author":"Kung","year":"2004","journal-title":"Cancer Cell"},{"issue":"19","key":"2019111904503105500_B53","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-05-1235","article-title":"Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity","volume":"65","author":"Kong","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"2019111904503105500_B54","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1158\/1535-7163.MCT-08-0198","article-title":"Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity","volume":"7","author":"Sullivan","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2019111904503105500_B55","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/sj.cdd.4401864","article-title":"Hypoxia and HIF-1alpha protect A549 cells from drug-induced apoptosis","volume":"13","author":"Schnitzer","year":"2006","journal-title":"Cell Death Differ"},{"issue":"10","key":"2019111904503105500_B56","doi-asserted-by":"crossref","first-page":"e108309","DOI":"10.1371\/journal.pone.0108309","article-title":"HIF-2\u03b1 regulates NANOG expression in human embryonic stem cells following hypoxia and reoxygenation through the interaction with an Oct-Sox cis regulatory element","volume":"9","author":"Petruzzelli","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"2019111904503105500_B57","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1101\/gad.1399906","article-title":"HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth","volume":"20","author":"Covello","year":"2006","journal-title":"Genes Dev"},{"issue":"1","key":"2019111904503105500_B58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc2274","article-title":"The interplay between MYC and HIF in cancer","volume":"8","author":"Dang","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2019111904503105500_B59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccr.2007.07.006","article-title":"HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation","volume":"12","author":"Gordan","year":"2007","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111904503105500_B60","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","article-title":"MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib","volume":"9","author":"Albajar","year":"2011","journal-title":"Mol Cancer Res"},{"issue":"8B","key":"2019111904503105500_B61","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/j.1582-4934.2008.00549.x","article-title":"Transcriptional regulation of survivin by c-Myc in BCR\/ABL-transformed cells: implications in anti-leukaemic strategy","volume":"13","author":"Fang","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"1","key":"2019111904503105500_B62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/47.1.1","article-title":"Acridine-a neglected antibacterial chromophore","volume":"47","author":"Wainwright","year":"2001","journal-title":"J Antimicrob Chemother"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/5\/655\/1404232\/blood745588.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/5\/655\/1404232\/blood745588.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T03:41:54Z","timestamp":1659066114000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/5\/655\/36810\/Targeting-chronic-myeloid-leukemia-stem-cells-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,8,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-10-745588","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}